Trial of Remdesivir for Moderate COVID-19 Shows Modest Results, Uncertainties
September 3rd 2020Odds of better clinical status were higher for patients with moderate COVID-19 who received a 5-day course of remdesivir than for those receiving standard care, according to the most recent randomized clinical trial of the antiviral drug.